Department of Biochemistry and Genetics, University of Navarra School of Sciences, 31008 Pamplona, Spain.
Interdisciplinary Brain Research Centre, Faculty of Medicine, Aligarh Muslim University, Aligarh 202002, India.
Cells. 2024 Apr 2;13(7):617. doi: 10.3390/cells13070617.
Glioblastoma is the most aggressive, malignant, and lethal brain tumor of the central nervous system. Its poor prognosis lies in its inefficient response to currently available treatments that consist of surgical resection, radiotherapy, and chemotherapy. Recently, the use of mesenchymal stem cells (MSCs) as a possible kind of cell therapy against glioblastoma is gaining great interest due to their immunomodulatory properties, tumor tropism, and differentiation into other cell types. However, MSCs seem to present both antitumor and pro-tumor properties depending on the tissue from which they come. In this work, the possibility of using MSCs to deliver therapeutic genes, oncolytic viruses, and miRNA is presented, as well as strategies that can improve their therapeutic efficacy against glioblastoma, such as CAR-T cells, nanoparticles, and exosomes.
胶质母细胞瘤是中枢神经系统中最具侵袭性、恶性和致命性的脑肿瘤。其预后不良的原因在于其对目前可用的治疗方法(包括手术切除、放疗和化疗)反应不佳。最近,间充质干细胞(MSCs)作为一种可能的针对胶质母细胞瘤的细胞治疗方法引起了极大的兴趣,因为它们具有免疫调节特性、肿瘤趋向性和分化为其他细胞类型的能力。然而,MSCs 似乎具有抗肿瘤和促肿瘤特性,具体取决于其来源组织。在这项工作中,提出了使用 MSCs 传递治疗基因、溶瘤病毒和 miRNA 的可能性,以及可以提高其对胶质母细胞瘤治疗效果的策略,如 CAR-T 细胞、纳米颗粒和外泌体。